Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019-Reference-Cited by-同舟云学术

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Published:2019-05 Issue:5 Volume:17 Page:414-423
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Brown Patrick A.¹,Wieduwilt Matthew²,Logan Aaron³,DeAngelo Daniel J.⁴,Wang Eunice S.⁵,Fathi Amir⁶,Cassaday Ryan D.⁷,Litzow Mark⁸,Advani Anjali⁹,Aoun Patricia¹⁰,Bhatnagar Bhavana¹¹,Boyer Michael W.¹²,Bryan Teresa¹³,Burke Patrick W.¹⁴,Coccia Peter F.¹⁵,Coutre Steven E.¹⁶,Jain Nitin¹⁷,Kirby Suzanne¹⁸,Liu Arthur¹⁹,Massaro Stephanie²⁰,Mattison Ryan J.²¹,Oluwole Olalekan²²,Papadantonakis Nikolaos¹³,Park Jae²³,Rubnitz Jeffrey E.²⁴,Uy Geoffrey L.²⁵,Gregory Kristina M.²⁶,Ogba Ndiya²⁶,Shah Bijal²⁷

Affiliation:

1. 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

2. 2UC San Diego Moores Cancer Center;

3. 3UCSF Helen Diller Comprehensive Cancer Center;

4. 4Dana-Farber/Brigham and Women’s Cancer Center;

5. 5Roswell Park Comprehensive Cancer Center;

6. 6Massachusetts General Hospital Cancer Center;

7. 7University of Washington/Seattle Cancer Care Alliance;

8. 8Mayo Clinic Cancer Center;

9. 9Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

10. 10City of Hope National Medical Center;

11. 11The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

12. 12Huntsman Cancer Institute at the University of Utah;

13. 13University of Alabama at Birmingham Comprehensive Cancer Center;

14. 14University of Michigan Rogel Cancer Center;

15. 15Fred & Pamela Buffett Cancer Center;

16. 16Stanford Cancer Institute;

17. 17The University of Texas MD Anderson Cancer Center;

18. 18Duke Cancer Institute;

19. 19University of Colorado Cancer Center;

20. 20Yale Cancer Center/Smilow Cancer Hospital;

21. 21University of Wisconsin Carbone Cancer Center;

22. 22Vanderbilt-Ingram Cancer Center;

23. 23Memorial Sloan Kettering Cancer Center;

24. 24St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

25. 25Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

26. 26National Comprehensive Cancer Network; and

27. 27Moffitt Cancer Center.

Abstract

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High expression of SLC27A2 predicts unfavorable prognosis and promotes inhibitory immune infiltration in acute lymphoblastic leukemia;Translational Oncology;2024-07

2. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia;Heliyon;2024-07

3. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study;Leukemia & Lymphoma;2024-04-17

4. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells;Hematology;2024-04-04

5. Ancillary Tests;Pediatric Pathology of Hematopoietic and Histiocytic Disorders;2024-02-15